Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients

Plain-language guide to PMID 18382904 (2008): randomized controlled trial study of HMG (Human Menopausal Gonadotropin) and Leuprolide.

Key Facts

PMID: 18382904
Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Year: 2008
Study type: Randomized Controlled Trial
Authors: Martínez F et al. (6 authors)
DOI: 10.1080/09513590801893331

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at HMG (Human Menopausal Gonadotropin) and Leuprolide.

To compare the clinical pregnancy rate in recipients of oocytes from donors treated with leuprorelin + human menopausal gonadotropins (hMG) with that obtained when the donors were treated with ganirelix + recombinant follicle-stimulating hormone (rFSH).

The secondary aim was to compare the donors' response to the two treatments.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

How the Study Was Run

In design terms this was a randomized study.

Because people in this HMG (Human Menopausal Gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A prospective, randomized, comparative study was conducted between January 2005 and November 2006 in a private hospital.

Donors were randomized to receive a long protocol of leuprorelin + hMG (group DI) or ganirelix + rFSH (group DII).

Their respective recipients were randomized to group RI or group RII, respectively.

What Was Measured

Topics PubMed links to this paper include Algorithms, Embryo Transfer, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone, Hormone Antagonists, Leuprolide and Menotropins.

What This Means in Plain Language

The paper is a randomized study of HMG (Human Menopausal Gonadotropin) and Leuprolide.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology), a journal based in England.

More context: the HMG (Human Menopausal Gonadotropin) compound page and the Leuprolide compound page, all human trials.

Our Notes on the Compounds

HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.

Leuprolide: A 9-amino-acid GnRH analog (Lupron, Eligard) that lowers sex-hormone levels with ongoing use; used in prostate cancer, endometriosis and early puberty.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.